Anti-inflammatory drug design using a molecular hybridization approach

Pharmaceuticals

Volumn 4, Issue 11, 2011, Pages 1450-1474

  Bosquesi, Priscila Longhin ^a   Melo, Thais Regina Ferreira ^a   Vizioli, Ednir Oliveira ^a   dos Santos, Jean Leandro ^a   Chung, Man Chin ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

Anti inflammatory; Hybridization; Multiple ligands; Mutual prodrug

Indexed keywords

1,5 DIARYLPYRAZOL 3 ONE DERIVATIVE; 3,4 DIPHENYL 1,2,5 OXADIAZOLE 2 OXIDE(3,4 DIPHENYLFUROXAN)DERIVATIVE; ACETYLSALICYLIC ACID; ANTIASTHMATIC AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT NITRIC OXIDE DONOR HYBRID; ASPIRIN NITRIC OXIDE DONOR HYBRID DERIVATIVE; CELECOXIB; COUMARIN LIPOIC ACID CONJUGATE; CYSTEINE ETHYL ESTER NAPROXEN NITROOXYPIVALOIC ACID HYBRID DERIVATIVE; DAPSONE THALIDOMIDE HYBRID; HYDROCORTISONE NITRIC OXIDE DONOR HYBRID DERIVATIVE; HYDROXYUREA THALIDOMIDE HYBRID; IBUPROFEN; IBUPROFEN NITRIC OXIDE DONOR HYBRID DERIVATIVE; INDOMETACIN; LASSBIO 468; LASSBIO 596; N DESOXY 3,4 DIPHENYL 1,2,5 OXADIAZOLE(3,4 DIPHENYLFURAN)DERIVATIVE; NITRIC OXIDE DONOR NONSTEROID ANTIINFLAMMATORY HYBRID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY PHTHALIMIDE HYBRID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY TAURINE HYBRID DERIVATIVE; PHTHALIMIDE DERIVATIVE; PRIMAQUINE KETOPROFEN CONJUGATE; PRODRUG; PYRAZOLE NITRIC OXIDE DONOR DERIVATIVE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC INFLAMMATION; COLORECTAL CANCER; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ERYTHEMA NODOSUM LEPROSUM; GASTROINTESTINAL SYMPTOM; HUMAN; MALARIA; MOLECULAR HYBRIDIZATION; NONHUMAN; PAW EDEMA; REVIEW; RHEUMATOID ARTHRITIS; SICKLE CELL ANEMIA; STRUCTURE ACTIVITY RELATION; TERATOGENICITY; ULCERATIVE COLITIS;

EID: 80455131270     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph4111450     Document Type: Review

References (65)

1. Barreiro, E.J.; Fraga, C.A.M.; Miranda, A.L.P.; Rodrigues, C.R. A química medicinal de N-acilidrazonas: Novos compostos-protótipos de fármacos analgésicos, antiinflamatórios e anti-trombóticos. Quim. Nova 2002, 25, 129-148.
2. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discov. Today 2004, 9, 641-651.
3. Vizioli, E.O. Ensaios Pré-clínicos de Híbridos Ftalimídicos e Pró-fármacos Taurínicos Derivados de Antiinflamatórios não Esteróides. Thesis, Faculdade de Ciências Farmacêuticas, UNESP, Araraquara, São Paulo, Brazil, 2009.
4. Rocha, M.D.; Viegas-Jr, C. Síntese de Novos Candidatos a Fármacos Híbridos Carbamoilacilidrazônicos Planejados Como Antiinflamatórios e Anticolinesterásicos. In Proceedings of 32a Reunião Anual da Sociedade Brasileira de Química, Centro de Convenções do Hotel Monte Real Resort, Águas de Lindóia, São Paulo, Brazil, 26-29 May 2008.
5. Tseng, S.; Pak, G.; Washenik, K.; Pomeranz, M.K.; Shupack, J.L. Rediscovering thalidomide: A review of its mechanism of action, side effects, and potential uses. J. Am. Acad. Dermatol. 1996, 35, 969-979.
6. Grosshans, E.; Illy, G. Thalidomide therapy for inflammatory dermatoses. Int. J. Dermatol. 1984, 23, 598-602.
7. Stirling, D.I. Thalidomide and its impact in dermatology. Semin. Cutan. Med. Surg. 1988, 17, 231-242.
8. Ordi-ros, J.; Cortes, F.; Cucurull, E.; Mauri, M.; Bujan, S.; Vilardell, M. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J. Rheumatol. 2000, 27, 1429-1433.
9. Lima, L.M.; Fraga, C.A.M.; Barreiro, E.J. O renascimento de um fármaco: Talidomida. Quim. Nova 2001, 24, 683-688.
10. Wannmacher, L. Inibidores seletivos de cicloxigenase-2 revisitados um ano depois. Uso racional de medicamentos. Temas Selecionados OPAS-OMS 2005, 2, 1-6.
11. Borges, L.G.; Froehlich, P.E. Talidomida: Novas perspectivas para utilização como antiinflamatório, imunossupressor e antiangiogênico. Rev. Assoc. Med. Bras. 2003, 49, 96-102.
12. Marriot, J.B.; Müller, G.; Dalgleish, A.G. Thalidomide as an emerging immunotherapeutic agent. Immunol. Today 1999, 20, 538-540.
13. Aggarwal, B.B.; Kunnumakkara, A.B.; Harikumar, K.B.; Gupta, S.R. Tharakan, S.T.; Koca, C.; Dey, S.; Sung, B. Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann. N. Y. Acad. Sci. 2009, 1171, 59-76.
14. Suryaprasad, A.G.; Prindiville, T. The biology of TNF blockade. Autoimmun. Rev. 2003, 2, 346-357.
15. Kodama, S.; Davis, M.; Faustman, D.L. The therapeutic potential of tumor necrosis factor for autoimmune disease: A mechanistically based hypothesis. Cell. Mol. Life Sci. 2005, 62, 1850-1862.
16. Popa, C.; Netea, M.G.; van Riel, P.L.; van der Meer, J.W.; Stalenhoef, A.F. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J. Lipid Res. 2007, 48, 751-762.
17. Clark, P.R.; Pober, J.S.; Kluger, M.S. Knockdown of TNFR1 by the sense strand of an ICAM-1 siRNA: Dissection of an off-target effect. Nucleic Acids Res. 2008, 36, 1081-1097.
18. Koch, A.; Zacharowski, K.; Boehm, O.; Stevens, M.; Lipfert, P.; von Giesen, H.J.; Wolf, A.; Freynhagen, R. Nitric oxide and pro-inflammatory cytokines correlate with pain intensity in chronic pain patients. Inflamm. Res. 2007, 56, 32-37.
19. Schenk, M.; Bouchon, A.; Seibold, F.; Mueller, C. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J. Clin. Invest. 2007, 117, 3097-3106.
20. Lima, L.M.; Castro, P.; Machado, A.L.; Fraga, C.A.M.; Lugnier, C.; Moraes, V.L.G.; Barreiro, E.J. Synthesis and anti-Inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg. Med. Chem. 2002, 10, 3067-3073.
21. Santos, J.L.; Yamasaki, P.R.; Chung, M.C.; Takashi, C.H.; Pavan, F.R.; Leite, C.Q. Synthesis and in vitro anti Mycobacterium tuberculosis activity of a series of phthalimide derivatives. Bioorg. Med. Chem. 2009, 17, 3795-3799.
22. Dos Santos, J.L.; Lanaro, C.; Lima, L.; Gambero, S.; Franco-Penteado, C.F.; Alexandre-Moreira, M.S.; Wade, M.; Yerigenahally, S.; Kutlar, A.; Meiler, S.E. et al. Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. J. Med. Chem. 2011, 54, 5811-5819.
23. Santos, J.L.; Oliveira, E.V.; Chung, M.C.; Menegon, R.F.; Blau, L. Derivados Ftalimídicos de Compostos Antiinflamatórios Não-Esteróide e/ou Moduladores de TNF-, Processo de sua Obtenção, Composições Farmacêuticas Contendo os Mesmos e Seus Usos no Tratamento de Doenças Inflamatórias; Depositada em 06 de Abril de 2009, INPI 020090033479.
24. Jung, Y.J.; Kim, H.H.; Kong, H.S.; Kim, Y.M. Synthesis and properties of 5-aminosalicyl-taurine as a colon-specific prodrug of 5-aminosalicylic acid. Arch. Pharm. Res. 2003, 26, 264-269.
25. Joo, K.; Lee, Y.; Choi, D.; Han, J.; Hong, S.; Kim, Y.M.; Jung, Y. An anti-inflammatory mechanism of taurine conjugated 5aminosalicylic acid against experimental colitis: Taurine chloramines potentiatesinhibitory effect of 5-aminosalicylic acid on IL-1beta-mediated NFkappaB activation. Eur. J. Pharmacol. 2009, 618, 91-97.
26. Vizioli, E.O.; Chung, M.C.; Menegon, R.F.; Blau, L.; Santos, J.L.; Longo, M.C. Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these. PCT/BR 2009/0409, WO/2009/124371.
27. Vizioli, E.O.; Chung, M.C.; Menegon, R.F.; Blau, L.; Santos, J.L.; Longo, M.C. Novel compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these, United States Patent Application 20110118303.
28. Brawek, B.; Löffler, M.; Wagner, K.; Huppertz, H.J.; Wendling, A.S.; Weyerbrock, A.; Jackisch, R.; Feuerstein, T.J. Reactive oxygen species (ROS) in the human neocortex: Role of aging and cognition. Brain Res. Bull. 2010, 81, 484-490.
29. Halliwell, R.B.; Aeschbach, J.L.; Löliger, J.; Aruoma, O.I. The characterization of antioxidants. Food Chem. Toxicol. 1995, 33, 601-617.
30. Garrido, G.; GonzáLez, D.; Delporte, C.; Backhouse, N.; Quintero, G.; Núnez-Sélles, A.J.; Morales, M.A. Analgesic and anti-inflammatory effects of Mangifera indica L. extract (Vimang). Phytother. Res. 2001, 15, 18-21.
31. Biewenga, G.P.; Haenen, G.R.; Bast, A. The pharmacology of the antioxidant lipoic acid. Gen. Pharmacol. 1997, 29, 315-331.
32. Packer, L.; Witt, E.H.; Tritschler, H.J. alpha-Lipoic acid as a biological antioxidant. Free Radic. Biol. Med. 1995, 19, 227-250.
33. Moini, H.; Packer, L.; Saris, N.E.L. Antioxidant and prooxidant activities of alpha-lipoic acid and dihydrolipoic acid. Toxicol. Appl. Pharmacol. 2002, 182, 84-90.
34. Gurer, H.; Ozgunes, H.; Oztezcan, S.; Ercal, N. Antioxidant role of alpha-lipoic acid in lead toxicity. Free Radic. Biol. Med. 1999, 27, 75-81.
35. Alleva, R.; Nasole, E.; di Donato, F.; Borghi, B.; Neuzil, J.; Tomasetti, M. alpha-Lipoic acid supplementation inhibits oxidative damage, accelerating chronic wound healing in patients undergoing hyperbaric oxygen therapy. Biochem. Biophys. Res. Commun. 2005, 333, 404-410.
36. Melagraki, G.; Afantitis, A.; Igglessi-Markopoulou, O.; Detsi, A.; Koufaki, M.; Kontogiorgis, C.; Hadjipavlou-Litina, D.J. Synthesis and evaluation of the antioxidant and anti-inflammatory activity of novel coumarin-3-aminoamides and their alpha-lipoic acid adducts. Eur. J. Med. Chem. 2009, 44, 3020-3026.
37. Kontogiorgis, C.A.; Hadjipavlou-Litina, D. Synthesis and antiinflammatory activity of coumarin derivatives. J. Med. Chem. 2005, 48, 6400-6408.
38. Ghate, M.; Manohar, D.; Kulkarni, V.; Shobha, R.; Kattimani, S.Y. Synthesis of vanillin ethers from 4-(bromomethyl) coumarins as anti-inflammatory agents. Eur. J. Med. Chem. 2003, 38, 297-302.
39. 2+ chelating activity. Acta Pharm. 2010, 60, 325-337.
40. Cena, C.; Boschi, D.; Tron, G.C.; Chegaev, K.; Lazzarato, L.; di Stilo, A.; Aragno, M.; Fruttero, R.; Gasco, A. Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants. Bioorg. Med. Chem. Lett. 2004, 14, 5971-5974.
41. Lolli, M.L.; Cena, C.; Medana, C.; Lazzarato, L.; Morini, G.; Manarini, G.S.; Fruttero, R.; Gasco, A. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 2001, 44, 3463-3468.
42. Cena, C.; Lolli, M.L.; Lazzarato, L.; Guaita, E.; Morini, G.; Coruzzi, G.; McElroy, S.P.; Megson, I.L.; Fruttero, R.; Gasco, A. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J. Med. Chem. 2003, 46, 747-754.
43. Turnbull, C.M.; Marcarino, P.; Sheldrake, T.A.; Lazzarato, L.; Cena, C.; Fruttero, R.; Gasco, A.; Fox, S.; Megson, I.L.; Rossi, A.G. A novel hybrid aspirin-NO-releasing compound inhibits TNF-alpha release from LPS activated human monocytes and macrophages. J. Inflamm. (Lond) 2008, 5, 1-10.
44. Gasco, A.; Boschi, D.; Chegaev, K.; Cena, C.; di Stilo, A.; Fruttero, R.; Lazzarato, L.; Rolando, B.; Tosco, P. Multitarget drugs: Focus on the NO-donor hybrid drugs. Pure Appl. Chem. 2008, 80, 1693-1701.
45. Lazzarato, L.; Donnola, M.; Rolando, B.; Chegaev, K.; Marini, E.; Cena, C.; di Stilo, A.; Fruttero, R.; Biondi, S.; Ongini, E. et al. (Nitrooxyacyloxy) methyl esters of aspirin as novel nitric oxide releasing aspirins. J. Med. Chem. 2009, 52, 5058-5068.
46. Lazzarato, L.; Chegaev, K.; Marini, E.; Rolando, B.; Borretto, E.; Guglielmo, S.; Joseph, S.; di Stilo, A.; Fruttero, R.; Gasco, A. New nitric oxide or hydrogen sulfide releasing aspirins. J. Med. Chem. 2011, 11, 5478-5484.
47. Hulsman, N.; Medema, J.P.; Bos, C.; Jongejan, A.; Leurs, R.; Smit, M.J.; Esch, I.J.P.; Richel, D.; Wijtmans, M. Chemical insights in the concept of hybrid drugs: The antitumor effect of nitric oxide-donating aspirin involves a quinone methide but not nitric oxide nor aspirin. J. Med. Chem. 2007, 50, 2424-2431.
48. Schäcke, H.; Döcke, W.D.; Asadullah, K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol. Ther. 2002, 96, 23-43.
49. Fang, L.; Zhang, Y.; Lehmann, J.; Wang, Y.; Ji, H.; Ding, D. Design and synthesis of furoxan-based nitric oxide-releasing glucocorticoid derivatives with potent anti-inflammatory activity and improved safety. Bioorg. Med. Chem. Lett. 2007, 17, 1062-1066.
50. Kartasasmita, R.E.; Laufer, S.; Lehmann, J. NO-donors (VII [I]): Synthesis and cyclooxygenase inhibitory properties of N- and S-nitrooxypivaloyl-cysteine derivatives of naproxen - a novel type of NO-NSAID. Arch. Pharm. (Weinheim) 2002, 335, 363-366.
51. Velazquez, C.; Rao, P.N.P.; McDonald, R.; Knaus, E.E. Synthesis and biological evaluation of 3,4-diphenyl-1,2,5-oxadiazole-2-oxides and 3,4-diphenyl-1,2,5-oxadiazoles as potential hybrid COX-2 inhibitor/nitric oxide donor agents. Bioorg. Med. Chem. 2005, 13, 2749-2757.
52. Velázquez, C.; Rao, P.N.P.; Knaus, E.E. Novel nonsteroidal antiinflammatory drugs possessing a nitric oxide donor diazen-1-ium-1,2-diolate moiety: Design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem. 2005, 48, 4061-4067.
53. Velazquez, C.A.; Rao, P.N.P.; Citro, M.L.; Keefer, L.K.; Knaus, E.E. O2-Acetoxymethyl-protected diazeniumdialate-based NSAIDs (NONO-NSAIDs): Synthesis, nitric oxide release, and biological evaluation studies. Bioorg. Med. Chem. 2007, 15, 4767-4774.
54. Abdellatif, K.R.A.; Chowdhury, M.A.; Dong, Y.; Chen, Q.H.; Knaus, E.E. Diazen-1-ium-1,2-diolated and nitrooxyethyl nitric oxide donor ester prodrugs of anti-inflammatory (E)-2-(aryl)-3-(4-methanesulfonylphenyl)acrylic acids: Synthesis, cyclooxygenase inhibition, and nitric oxide release studies. Bioorg. Med. Chem. 2008, 16, 3302-3308.
55. Abdellatif, K.R.A.; Chowdhury, M.A.; Dong, Y.; Das, D.; Yu, G.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Dinitroglyceryl and diazen-1-ium-1,2-diolated nitric oxide donor ester prodrugs of aspirin, indomethacin and ibuprofen: Synthesis, biological evaluation and nitric oxide release studies. Bioorg. Med. Chem. Lett. 2009, 19, 3014-3018.
56. Shoman, M.E.; Abdel-Aziz, M.; Aly, O.M.; Farag, H.H.; Morsy, M.A. Synthesis and investigation of anti-inflammatory activity and gastric ulcerogenicity of novel nitric oxide-donating pyrazoline derivatives. Eur. J. Med. Chem. 2009, 44, 3068-3076.
57. Bhandari, S.V.; Dangre, S.C.; Bothara, K.G.; Patil, A.A.; Sarkate, A.P.; Lokwani, D.K.; Gore, S.T.; Deshmane, B.J.; Raparti, V.T.; Khachane, C.V. Design, synthesis and pharmacological screening of novel nitric oxide donors containing 1,5-diarylpyrazolin-3-one as nontoxic NSAIDs. Eur. J. Med. Chem. 2009, 44, 4622-4636.
58. Ranatunge, R.R.; Augustyniak, M.; Bandarage, U.K.; Earl, R.A.; Ellis, J.L.; Garvey, D.S.; Janero, D.R.; Letts, L.G.; Martino, A.M.; Murty, D.R.; et al. Synthesis and selective cyclooxygenase-2 inhibitory activity of a series of novel, nitric oxide donorcontaining pyrazoles. J. Med. Chem. 2004, 47, 2180-2193.
59. Sarkate, A.P.; Lokwani, D.K.; Patil, A.A.; Bhandari, S.V.; Bothara, K.G. Synthesis and evaluation of anti-inflammatory, analgesic, ulcerogenicity and nitric oxide-releasing studies of novel ibuprofen analogs as nonulcerogenic derivatives. Med. Chem. Res. 2010, 20, 795-808.
60. Hinz, B.; Brune, K.J. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther. 2002, 300, 367-375.
61. Mukherjee, D. Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem. Pharmacol. 2002, 63, 817-821.
62. Khaled, R.A.; Abdellatif, Y.D.; Chen, Q.H.; Chowdhury, M.A.; Knaus, E.E. Novel (E)-2-(aryl)-3-(4-methanesulfonylphenyl) acrylic ester prodrugs possessing a diazen-1-ium-1,2-diolate moiety: Design, synthesis, cyclooxygenase inhibition, and nitric oxide release studies. Bioorg. Med. Chem. 2007, 15, 6796-6801.
63. Chowdhury, M.A.; Abdellatif, K.R.A.; Dong, Y.; Knaus, E.E. Synthesis of new 4-[2-(4-methyl(amino)sulfonylphenyl)-5-trifluoromethyl-2H-pyrazol-3-yl]-1,2,3,6-tetrahydropyridines: A search for novel nitric oxide donor anti-inflammatory agents. Bioorg. Med. Chem. 2008, 16, 8882-8888.
64. Boschi, D.; Lazzarato, L.; Rolando, B.; Filieri, A.; Cena, C.; di Stilo, A.; Fruttero, R.; Gasco, A. Nitrooxymethyl substituted analogues of celecoxib: Synthesis and pharmacological characterization. Chem. Biodivers. 2009, 6, 369-379.
65. Chowdhury, M.A.; Abdellatif, K.R.A.; Dong, Y.; Yu, G.; Huang, Z.; Rahman, M.; Das, D.; Velázquez, C.A.; Suresh, M.R.; Knaus, E.E. Celecoxib analogs possessing a N-(4-nitrooxybutyl)piperidin-4-yl or N-(4-nitrooxybutyl)-1,2,3,6-tetrahydropyridin-4-yl nitric oxide donor moiety: Synthesis, biological evaluation and nitric oxide release studies. Bioorg. Med. Chem. Lett. 2010, 20, 1324-1329.